QUOTE AND NEWS
StreetInsider.com  Oct 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+Reports+Dosing+in+Novartis+%28NVS%29+Phase+12+Using+Bilateral+Hearing+Loss+Treatment+Tech/9951089.html for the full story.
StreetInsider.com  Oct 20  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/GenVec+%28GNVC%29+Director+Horovitz+to+Retire/9923120.html for the full story.
SeekingAlpha  Mar 28  Comment 
GenVec, Inc. (GNVC) Q4 2013 Earnings Conference Call March 28, 2014 10:00 a.m. ET Executives Douglas Swirsky - President and CEO Douglas Brough - Chief Scientific Officer James Lambert - Senior Director of Accounting & Finance ...
StreetInsider.com  Mar 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/GenVec%2C+Inc.+New+%28GNVC%29+Narrows+Q4+Loss+on+Lighter+Revs%3B+Guides+FY14+Cash+Burn/9326055.html for the full story.
TheStreet.com  Mar 27  Comment 
NEW YORK (TheStreet) -- Shares of GenVec Inc.  were up 12.83% to $2.99 in aftermarket trading Thursday. The jump comes ahead of the company posting its fiscal 2013 fourth quarter earnings on Friday.Consensus EPS forecast for the company is - 10...
StreetInsider.com  Mar 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/GenVec+%28GNVC%29+to+Place+%249M+of+Common+at+%243.15Share/9278256.html for the full story.
Benzinga  Feb 24  Comment 
In a report published Monday, H.C. Wainwright & Co. analyst Reni Benjamin initiated coverage on GenVec (NASDAQ: GNVC) with a Buy rating and $9.00 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of GenVec...
StreetInsider.com  Dec 12  Comment 
52-Week High: GenVec, Inc. (Nasdaq: GNVC) $2.89. GenVec higher after reporting that on December 4, 2013, the National Institutes of Health's Recombinant DNA Advisory Committee (RAC) unanimously approved the protocol for initiation of a Phase 1...
StreetInsider.com  Dec 12  Comment 
ImmunoCellular Therapeutics, Ltd. (NYSE: IMUC) 59.2% LOWER; announced that ICT-107, its dendritic cell-based vaccine, demonstrated a statistically significant increase in progression-free survival (PFS) in patients with newly diagnosed...
Benzinga  Dec 12  Comment 
GenVec (NASDAQ: GNVC) jumped 54.60% to $2.69. GenVec's trailing-twelve-month revenue is $7.40 million. NTS Realty Holdings LP (NYSE: NLP) rose 49.05% to $7.05 after the company reached an agreement in principle with the plaintiffs to settle the...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki